• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Cover of Self-Administered Drug Treatments for Acute Migraine Headache

Self-Administered Drug Treatments for Acute Migraine Headache

Technical Reviews, No. 2.4

Contributing Authors: , DPhil, , MD, MHSc, , BA, , MD, and , PhD.

Center for Clinical Health Policy Research, Duke University

Structured Abstract

Objective:

The objective was to identify and summarize evidence from controlled trials on the efficacy and tolerability of self-administered drug treatments for acute migraine headache.

Search Strategy:

A strategy combining the MeSH term “headache” (exploded) and a previously published strategy for identifying randomized controlled trials was used on the January 1966 to December 1996 MEDLINE database. Other computerized bibliographic databases, textbooks, and experts were also utilized.

Selection Criteria:

English-language controlled trials involving patients with acute migraine headache in which at least one treatment offered was a self-administered drug treatment were included.

Data Collection and Analysis:

The number of patients obtaining headache relief according to an a priori definition of at least a 50% reduction in pain severity was recorded and used to calculate odds ratios for headache relief Measures of pain severity reported as group means (and standard deviations) were used to calculate standardized mean differences (or effect sizes). Where similar trials provided data, meta-analysis of efficacy measures was performed. The identity and rates of adverse events were recorded and statistically compared.

Main Results:

Placebo-controlled trials support the efficacy of a number of self-administered treatments for acute migraine, including non-steroidal anti-inflammatory drugs (NSAIDs), dihydroergotamine (DHE) nasal spray, sumatriptan (in subcutaneous, oral, and intranasal formulations), and opiate analgesics (codeine and butorphanol). Evidence supporting the efficacy of ergot alkaloids and isometheptene compounds is weaker. Comparisons among alternative drug treatments are few in number and mostly inconclusive. Controlled trials of antinauseants or caffeine used in conjunction with ergots or NSAIDs do not show a significant adjuvant effect on pain relief. Ergotamine tartrate was associated with the highest rate of adverse events, principally nausea, but concomitant administration of antinauseants or caffeine appear to improve its tolerability.

Conclusions:

Several self-administered drugs appear to be effective for the treatment of acute migraine. The inconclusive comparisons among classes of drugs and individual agents suggest that the choice among alternatives for the treatment of acute migraine may, for the present, depend more on side effects and contraindications than on data about efficacy.

Project Directors: Douglas C McCrory, MD, MHSc, David B Matchar, MD. Project Manager: Rebecca N Gray, DPhil. Research Assistants: Louise Nobles, RN, Susan Farese, RN, Pramod Gumpeni. Technical Advisors: Jay Rosenberg, MD, Stephen Silberstein, MD, Seymour Solomon, MD, William Young, MD, James Adelman, MD, David Buchholz, MD, David Capobianco, MD, Debra Elliott, MD, David Kudrow, MD, Ninan Mathew, MD, Lawrence Newman, MD, Nabih Ramadan, MD, Carl Sadowsky, MD, Elliott Schulman, MD, Stewart Tepper, MD, Paul Winner, MD. AHCPR Project Officer: Ernestine Murray, RN, MAS.

Prepared for: Agency for Health Care Policy and Research, Department of Health and Human Services, U.S. Public Health Service, Rockville, Maryland. Contract No. 290-94-2025. Prepared by: Center for Clinical Health Policy Research, Duke University.

Suggested citation:

Duke University, Center for Clinical Health Policy Research. Self-Administered Drug Treatments for Acute Migraine Headache. Technical Review 2.4. February 1999. (Prepared for the Agency for Health Care Policy and Research under Contract No. 290-94-2025. Available from the National Technical Information Service; NTIS Accession No. PB99-127854.)

This document does not necessarily represent the views of the Department of Health and Human Services. It is available from the National Technical Information Service at 1-800-553-6847.

Bookshelf ID: NBK45465PMID: 20945568
PubReader format: click here to try

Views

Related information

Related citations in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...